key: cord-0721658-opb39q4w
authors: Foucard, Cendrine; San‐Galli, Aurore; Tarrano, Clément; Chaumont, Hugo; Lannuzel, Annie; Roze, Emmanuel
title: Acute cerebellar ataxia and myoclonus with or without opsoclonus: a parainfectious syndrome associated with COVID‐19
date: 2021-01-25
journal: Eur J Neurol
DOI: 10.1111/ene.14726
sha: cf0f2f99affaf960dd6fac0528760a83d94285ef
doc_id: 721658
cord_uid: opb39q4w

BACKGROUND: Patients with COVID‐19 can have central or peripheral neurological manifestations. METHODS: We report the case of two patients with acute cerebellar ataxia and myoclonus (ACAM) associated with COVID‐19 (with video) and discuss five previously reported patients. RESULTS: ACAM started between ten days and six weeks after the first manifestations of COVID‐19. Opsoclonus or ocular flutter was present in 4 patients. Patients were treated with intravenous immunoglobulins and/or steroids except for one patient, resulting in a striking improvement within a week. CONCLUSION: ACAM with or without opsoclonus belongs to the wide spectrum of neurological manifestations associated with COVID19. It is important to recognize this possible manifestation since early treatment allows for rapid recovery.

Patients with COVID-19 infection can have neurological manifestations reflecting involvement of the central nervous system (mainly subacute encephalopathy and stroke), the peripheral nervous system (mostly Guillain-Barré syndrome and cranial nerve palsy), or the combination thereof (1) . Opsoclonusmyoclonus-ataxia syndrome (OMAS) is an immune-mediated movement disorder and is mostly parainfectious or paraneoplastic (2) . It is characterized by the variable association of opsoclonus, myoclonus, cerebellar ataxia, behavioral and sleep disturbances (2) . Immune-mediated acute cerebellar ataxia and myoclonus (ACAM) in the absence of opsoclonus is rare. It is not clear whether ACAM belongs to the spectrum of OMAS, or it is a distinct entity close to OMAS (2).

We report two cases of ACAM associated with COVID-19. Detailed characteristics of the patients are shown in the table. ACAM respectively started ten days and six weeks after the onset of typical features of COVID-19 infection (table). Patient 1 had confusion with myoclonic jerks of the four limbs, ataxic dysarthria, and an opsoclonus (video). Patient 2 presented a rapidly progressive cerebellar syndrome with stimulus-sensitive action myoclonus (video). Cerebral MRI and cerebrospinal fluid (CSF) analysis were normal. There was no epileptic activity on EEG. Video-oculography confirmed the opsoclonus in patient 1.

Autoimmune and paraneoplastic anti-neuronal antibodies were negative. COVID-19 diagnosis was established by the presence of COVID-19 specific antibodies in the patient's serum. Both patients were treated with intravenous immunoglobulins associated with steroids in patient 1, resulting in a striking improvement within a week. All procedures were done according to our institution's ethical standards in accordance with the Declaration of Helsinki. The patients consented to videotape and publication.

Including the two patients reported here, seven patients have been reported with ACAM associated with COVID-19 (3-7) (table). They were male and aged from 44 to 83. ACAM started between ten days and six weeks after the first manifestations of COVID-19. Opsoclonus was present in three patients, ocular flutter in one patient. One was treated with intravenous immunoglobulins, one with intravenous steroids, and four with the combination thereof. The remaining patient only received symptomatic treatment with levetiracetam. They all had a clear improvement within a week after treatment onset. As for various viral infections, such as HIV, CMV, HSV, adenovirus, and enterovirus (2), a variable combination of opsoclonus, myoclonus, and ataxia could be observed in association with COVID-19. The mechanism is likely immunemediated, as supported by the normality of the MRI and CSF (8) . These observations are important for clinical practice since early treatment with immunoglobulin and/or steroids allows rapid recovery (8 

This article is protected by copyright. All rights reserved 

Neurological associations of COVID-19

Update on opsoclonus-myoclonus syndrome in adults

Opsoclonus myoclonus ataxia syndrome (OMAS) in the setting of COVID-19 infection

Myoclonus and cerebellar ataxia following Coronavirus Disease 2019 (COVID-19)

Opsoclonus Myoclonus Ataxia Syndrome Related to the Novel Coronavirus (COVID-19)

Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from 18F-FDG PET Imaging and Neuronal Autoantibodies

Reversible Myoclonus-Ataxia as a Postinfectious Manifestation of COVID-19

Principles and approaches to the treatment of immune-mediated movement disorders